Clinical Trials Browser

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer × Fulvestrant × 90 days × Clear all

NCT06065748 2026-03-09

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer